Anagram Therapeutics is a biopharmaceutical company based in Framingham, MA, dedicated to developing breakthrough orally-delivered enzyme therapeutics for rare, life-threatening diseases. Their focus lies in treating malabsorption syndromes and nutrient metabolism disorders caused by enzyme deficiencies or genetic mutations, aiming to provide effective solutions for individuals who are currently inadequately treated or have no treatment options at all.
With a team of world-class researchers and collaborators, Anagram Therapeutics is powered by innovative technology and expertise in enzymes and gastrointestinal physiology. They are committed to realigning and reimagining orally-delivered enzymes to make a meaningful difference in the lives of infants, children, and adults affected by these debilitating conditions, as well as their families.
Generated from the website